Overcoming Electrochemiluminescence Immunoassay (ECLIA) Limitations: Conformation-Independent Quantitation of a Therapeutic Antibody by LC–MS/MS
Analytical Chemistry · 2026
DOI: 10.1021/acs.analchem.5c07732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2026. Verfasst von Claudia Gaither und 6 weiteren Autor:innen. Beteiligte Einrichtung: Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QuébecJ2S 2A4, Canada. Hauptthemen laut MEDLINE: Luminescent Measurements, Immunoglobulin G, Electrochemical Techniques, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: McGill University, Genome Canada, G??nome Qu??bec.
Abstract (Originalsprache)
Monoclonal antibody therapies have transformed cancer treatment by enabling targeted intervention even in advanced disease stages. However, reliable monitoring of circulating therapeutic antibody levels is critical to ensuring efficacy and patient safety. This study investigates the limitations of an electrochemiluminescence immunoassay (ECLIA) in quantifying a therapeutic immunoglobulin G2 (IgG2) antibody, known to undergo conformational changes in vivo. We observed that the ECLIA failed to reflect increasing antibody concentrations in patient plasma, instead producing a plateau effect. This discrepancy was attributed to the ECLIA’s reliance on the intact structural conformation of the antibody, which may be altered during circulation. In contrast, a mass spectrometry (MS)-based approach successfully quantified the accumulating antibody levels over time, independent of conformational state. These findings highlight the need for alternative quantitation strategies in clinical settings, particularly when structural heterogeneity may compromise the ECLIA performance. Mass spectrometry provides a robust and reliable option for monitoring therapeutic antibodies under these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QuébecJ2S 2A4, Canada.
- MRM Proteomics Inc., Montréal, QuébecH2X 3X8, Canada.
- Alethia Biotherapeutics ULC, MontréalH2X 3X8, Québec, Canada.
- Gerald Bronfman Department of Oncology, Jewish General Hospital, Montréal, QuébecH3T 1E2, Canada.
- Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QuébecH3T 1E2, Canada.
- Warren Y. Soper Clinical Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General, Hospital, Montréal, QuébecH3T 1E2, Canada.
ORCID-Profile: Christoph H Borchers
Förderung
- McGill University
- Genome Canada
- G??nome Qu??bec
- Jewish General Hospital
- Fondation De Famille Alvin Segal
- Warren Y. Soper Charitable Trust
Zitieren
APA
Gaither, C., Popp, R., Maheshwari, P., Lemus, M., Laurin, J., Filion, M., & Borchers, C. H. (2026). Overcoming Electrochemiluminescence Immunoassay (ECLIA) Limitations: Conformation-Independent Quantitation of a Therapeutic Antibody by LC–MS/MS. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.5c07732
Vancouver
Gaither C, Popp R, Maheshwari P, Lemus M, Laurin J, Filion M, et al. Overcoming Electrochemiluminescence Immunoassay (ECLIA) Limitations: Conformation-Independent Quantitation of a Therapeutic Antibody by LC–MS/MS. Analytical Chemistry. 2026. doi:10.1021/acs.analchem.5c07732
BibTeX
@article{Gaither2026,
author = {Gaither, Claudia and Popp, Robert and Maheshwari, Pradyumn and Lemus, Mauricio and Laurin, Julie and Filion, Mario and Borchers, Christoph H},
title = {Overcoming Electrochemiluminescence Immunoassay (ECLIA) Limitations: Conformation-Independent Quantitation of a Therapeutic Antibody by LC–MS/MS},
journal = {Analytical Chemistry},
year = {2026},
doi = {10.1021/acs.analchem.5c07732}
}
EUVIMED